PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
FLEX: From Genomic Profiling to Real-World Insights in 30,000 Patients with Early-Stage Breast Cancer
Publication: SABCS 2025, Presentation ID: PS5-09-19 Authors: Gold et al. Title: FLEX: From Genomic Profiling to Real-World Insights in 30,000 Patients with Early-Stage Breast Cancer Introduction: Treatment approaches for early-stage breast cancer (EBC) have advanced significantly in recent decades, with the addition of HER2-targeted therapies, immunotherapy, and personalized chemotherapy. Read More
Distinct Immune and Metabolic profiles in Latin American Breast Cancer Patients With Obesity Enrolled in FLEX
Publication: SABCS 2025, Presentation ID: PS4-09-09 Authors: Mazo Canola et al. Title: Distinct Immune and Metabolic profiles in Latin American Breast Cancer Patients With Obesity Enrolled in FLEX Introduction: Latin American (LA) women are more often diagnosed with aggressive early breast cancer (EBC) than Non-Hispanic White (NHW) women1. Prior Read More
HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study
Publication: SABCS 2025, Presentation ID: PS3-08-17 Authors: Mahtani et al. Title: HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study Introduction: Women ≥ 70 years of age are less likely to receive chemotherapy (CT) due to Read More
70-Gene Signature High Risk Classification Provides Stronger Prognostic Value Than Histologic Grade in HR+HER2– Early Breast Cancer
Publication: SABCS 2025, Presentation ID: PS5-04-19 Authors: Cobain et al. Title: Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancer Introduction: Pivotal trials of immunotherapy and CDK4/6 inhibitors in early-stage hormone-receptor positive (HR+) HER2 negative (HER2–) breast cancer have Read More
Improved 3-Year IDFS With Anthracycline-Based Therapy for Patients With 70-Gene Signature High 2, Luminal B, HR+HER2- Early-Stage Breast Cancer
Publication: SABCS 2025, Presentation ID: PS2-07-03 Authors: O’Shaugnessy et al. Title: Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancer Introduction: ABC trials found no significant differences in outcomes among patients with clinically high-risk HR+, HER2- breast cancer when Read More
Leveraging Real-World Evidence To Personalize Adjuvant Therapy in HR+/HER2- Early Breast Cancer
Publication: JNCI Cancer Spectrum, 2025, 9(5), pkaf092 Authors: Yael Bar, MD, PhD , Steven J. Isakoff , MD, PhD , Seth A. Wander , MD, PhD Title: Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer Abstract: The use of gene expression assays (GEAs) to assess Read More
MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data
Publication: JNCI Cancer Spectrum, August 2025 Authors: Brufsky et al. Title: MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data Abstract Background: Gene expression assays help personalize adjuvant chemotherapy decisions for hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer (EBC). The 70-gene risk of distant-recurrence signature, MammaPrint, Read More
